We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Apotex’s decision to launch its generic version of the blockbuster blood thinner Plavix long before a court decides if it has a valid patent challenge may not be as risky as it first seemed, according to newly released details of its settlement agreement with sanofi-aventis and Bristol-Myers Squibb (BMS).